author-photo

Michael ODwyer

National University of Ireland, Galway

27

Papers

158

Citations

Citation Trend

Filter By

Papers (21) Sort By

Journal Conference Others

Venetoclax and Epigenetic Modifiers: Promising Novel Combinations for the Treatment of Multiple Myeloma

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Single Cell Transcriptomics Revealed Molecular Alterations in AML Cell Clusters Relevant to Refractory Disease at Relapse

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone: Update of the Phase 3 MAIA Trial

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Meaningful Changes in Patient-Reported Outcomes in Relation to Best Clinical Response and Disease Progression: Post Hoc Analyses from MAIA

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Stromal cell sialylation suppresses T cells in inflammatory tumour microenvironments: A new tumour stromal cell immune checkpoint?

2021 bioRxiv
Show All
- Source
- Cite
- Save
Citations (0)
CD38-specific chimeric antigen receptor expressing natural killer KHYG-1 cells: A proof of concept for an "Off the Shelf" therapy for multiple myeloma

2021
Show All
- Source
- Cite
- Save
Citations (0)
Realizing Innate Potential: CAR-NK Cell Therapies for Acute Myeloid Leukemia.

2021 Cancers
- Mark Gurney
- Michael ODwyer
Show All
- Source
- Cite
- Save
Citations (3)
P-094: ABT-199 and epigenetic modifiers: promising novel combinations for the treatment of Multiple Myeloma

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
Cybord-Dara in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Follow up Results from the 16-Bcni-001/Ctrial-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
MM-155: Phase 3 MAIA Study: Overall Survival (OS) Results with Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) vs Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TIE-NDMM)

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (1)